Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients

Summary

Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder of angiogenesis associated with disabling epistaxis. Management of these nose bleedings requires more effective treatment. Propranolol, a beta-blocker, is a potentially useful therapeutic considering its anti-angiogenic properties. Our objective is to explore the efficacy of propranolol, three months after its introduction, on the cumulative duration of epistaxis in HHT patients.

Timeline

Start

2020-06-23

Primary completion

2022-05-19

Completion

2022-05-19

Drugs

Indications